title: P2Y13 receptors mediate presynaptic inhibition of acetylcholine release induced by adenine nucleotides at the mouse neuromuscular junction.
abstract: It is known that adenosine 5'-triphosphate (ATP) is released along with the neurotransmitter acetylcholine (ACh) from motor nerve terminals. At mammalian neuromuscular junctions (NMJs), we have previously demonstrated that ATP is able to decrease ACh secretion by activation of P2Y receptors coupled to pertussis toxin-sensitive Gi/o protein. In this group, the receptor subtypes activated by adenine nucleotides are P2Y12 and P2Y13. Here, we investigated, by means of pharmacological and immunohistochemical assays, the P2Y receptor subtype that mediates the modulation of spontaneous and evoked ACh release in mouse phrenic nerve-diaphragm preparations. First, we confirmed that the preferential agonist for P2Y12-13 receptors, 2-methylthioadenosine 5'-diphosphate trisodium salt hydrate (2-MeSADP), reduced MEPP frequency without affecting MEPP amplitude as well as the amplitude and quantal content of end-plate potentials (EPPs). The effect on spontaneous secretion disappeared after the application of the selective P2Y12-13 antagonists AR-C69931MX or 2-methylthioadenosine 5'-monophosphate triethylammonium salt hydrate (2-MeSAMP). 2-MeSADP was more potent than ADP and ATP in reducing MEPP frequency. Then we demonstrated that the selective P2Y13 antagonist MRS-2211 completely prevented the inhibitory effect of 2-MeSADP on MEPP frequency and EPP amplitude, whereas the P2Y12 antagonist MRS-2395 failed to do this. The preferential agonist for P2Y13 receptors inosine 5'-diphosphate sodium salt (IDP) reduced spontaneous and evoked ACh secretion and MRS-2211 abolished IDP-mediated modulation. Immunohistochemical studies confirmed the presence of P2Y13 but not P2Y12 receptors at the end-plate region. Disappearance of P2Y13 receptors after denervation suggests the presynaptic localization of the receptors. We conclude that, at motor nerve terminals, the Gi/o protein-coupled P2Y receptors implicated in presynaptic inhibition of spontaneous and evoked ACh release are of the subtype P2Y13. This study provides new insights into the types of purinergic receptors that contribute to the fine-tuning of cholinergic transmission at mammalian neuromuscular junction.
authors.affiliation: Laboratorio de Neurofisiología, Instituto de Investigaciones Médicas Lanari, IDIM-CONICET, Universidad de Buenos Aires, Combatientes de Malvinas 3150 (CP 1427), Buenos Aires, Argentina.
authors.forename: Juan F
authors.initials: JF
authors.lastname: Guarracino
authors.affiliation: Laboratorio de Neurofisiología, Instituto de Investigaciones Médicas Lanari, IDIM-CONICET, Universidad de Buenos Aires, Combatientes de Malvinas 3150 (CP 1427), Buenos Aires, Argentina.
authors.forename: Alejandro R
authors.initials: AR
authors.lastname: Cinalli
authors.affiliation: Departamento de Biología, Universidad Argentina John F Kennedy, Sarmiento 4564 (CP 1197), Buenos Aires, Argentina.
authors.forename: Verónica
authors.initials: V
authors.lastname: Fernández
authors.affiliation: Departamento de Biología, Universidad Argentina John F Kennedy, Sarmiento 4564 (CP 1197), Buenos Aires, Argentina.
authors.forename: Liliana I
authors.initials: LI
authors.lastname: Roquel
authors.affiliation: Laboratorio de Neurofisiología, Instituto de Investigaciones Médicas Lanari, IDIM-CONICET, Universidad de Buenos Aires, Combatientes de Malvinas 3150 (CP 1427), Buenos Aires, Argentina. Electronic address: adrianalosavio@gmail.com.
authors.forename: Adriana S
authors.initials: AS
authors.lastname: Losavio
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000244:Adenosine Diphosphate / Q000008:administration & dosage / Q000031:analogs & derivatives; D000249:Adenosine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives; D000818:Animals; D005260:Female; D008297:Male; D051379:Mice; D055369:Miniature Postsynaptic Potentials; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism*; D058910:Purinergic P2 Receptor Agonists / Q000008:administration & dosage; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D058925:Receptors, Purinergic P2Y12 / Q000502:physiology; D013873:Thionucleotides / Q000008:administration & dosage
chemical_list: C548577:P2ry12 protein, mouse; C486689:P2ry13 protein, mouse; D058910:Purinergic P2 Receptor Agonists; D058921:Purinergic P2Y Receptor Antagonists; D018048:Receptors, Purinergic P2; D058925:Receptors, Purinergic P2Y12; D013873:Thionucleotides; C002480:methylthio-ADP; D000249:Adenosine Monophosphate; D000244:Adenosine Diphosphate; C117446:cangrelor; D000109:Acetylcholine
keywords: 2-MeSADP; ATP; P2Y receptors; mammalian neuromuscular junction; presynaptic inhibition